Clinical Trials in Czechia

• Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended
  2023-507096-21-00 Phase III Chronic or Episodic Migraine (Migraine without aura, migrain… AbbVie Deutschland GmbH & Co. KG
• A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended
  2023-505203-23-01 Phase III Severe asthma with an eosinophilic phenotype Glaxosmithkline Research & Development Limited
• Study of efficacy, safety, and tolerability of LNA043 in patients with symptomatic knee osteoarthritis Ended
  2023-509937-37-00 Phase II Osteoarthritis Novartis Pharma AG
• Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathi… Ended
  2024-515964-30-00 Phase II Interstitial Lung Diseases (ILD), including but not limited … Avalyn Pharma Inc.
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Ended
  2023-503387-16-00 Phase II Classical Hodgkin Lymphoma Seagen Inc.
• A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan… Ended
  2024-513569-38-00 Phase II/III Crohn's Disease Arena Pharmaceuticals Inc.
• The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended
  2023-510174-13-00 Phase III Chronic Obstructive Pulmonary Disease (COPD) Chiesi Farmaceutici S.p.A.
• The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-510175-60-00 Phase III Chronic obstructive pulmonary disease (COPD) and Chronic Br… Chiesi Farmaceutici S.p.A.
• Long-term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks Ended
  2024-510777-18-00 Phase III Hereditary angioedema CSL Behring LLC
• "A Phase 3 study of Viltolarsen in boys with Duchenne Muscular Dystrophy (DMD)" Ended
  2023-507146-91-00 Phase III Duchenne Muscular Dystrophy (DMD) Ns Pharma Inc.
• European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended
  2022-500385-99-00 Phase III SARS-CoV II infection (Coronavirus disease) Oslo University Hospital Hf
• A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma Ended
  2023-503280-42-00 Phase III Metastatic Clear Cell Renal Cell Carcinoma Bristol-Myers Squibb Services Unlimited Company
• Phase 2 study of Pembrolizumab given every 6 weeks to participants diagnosed with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL… Ended
  2024-510979-38-00 Phase II Relapsed or refractory Classical Hodgkins Lymphoma and relap… Merck Sharp & Dohme LLC
• A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended
  2024-512123-37-00 Phase III Parkinson's disease Cerevel Therapeutics LLC
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended
  2023-506918-45-00 Phase III Mild cognitive impairment (MCI) or mild dementia, both of th… Novo Nordisk A/S
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended
  2023-506919-18-00 Phase III Mild cognitive impairment (MCI) or mild dementia, both of th… Novo Nordisk A/S
• A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S… Ended
  2023-505786-88-00 Phase III Severe and inadequately controlled asthma Astrazeneca AB
• Investigation to assess the effects of zalunfiban in patients with an acute heart attack Ended
  2023-508485-15-00 Phase III Subjects with documented STEMI, presenting with persistent i… Celecor Therapeutics Inc.
• Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER… Ended
  2024-512012-21-00 Phase III Chronic Obstructive Pulmonary Disease Sanofi-Aventis Recherche & Developpement
• Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER… Ended
  2024-512013-41-00 Phase III Chronic Obstructive Pulmonary Disease Sanofi-Aventis Recherche & Developpement
• A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1 P… Ended
  2023-509449-10-00 Phase II Squamous cell carcinoma of the head and neck (SCCHN) F. Hoffmann-La Roche AG
• GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies Ended
  2023-507086-26-00 Phase I (FiH) Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Larg… Genmab A/S
• Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other select… Ended
  2024-513379-41-00 Phase I Advanced, relapsed Clear Cell Renal Cell Carcinoma Novartis Pharma AG
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 Phase III IgA Nephropathy Novartis Pharma AG

Showing 1,393–1,416 of 1,513 trials